Shaalan Beg MD MBA FASCO retweeted
Amazing! I may be partial to Dallas, but DFW never fails to impress! Thank you for lighting up the night year after year in support of the mission to end pancreatic cancer! 💜
@PanCANDFW @gingercbs11 @wfaaweather @aberkenblit @JulieFleshman
On World Pancreatic Cancer Day, cities across the United States joined the @WorldPCC in illuminating landmarks purple after dusk to raise awareness for pancreatic cancer. 💜🌎
From San Francisco and Portland to Chicago, Dallas, Atlanta, Pittsburgh, Boston and beyond, communities came together to illuminate landmarks in purple and show their support for everyone affected by this disease.
A special thank you to the dedicated PanCAN volunteers who coordinated these illuminations and made them possible. All together, we can raise awareness. 🎗️
Shaalan Beg MD MBA FASCO retweeted
In Pancreatic Cancer “Challenging Case” discussion with @MallaMidhun & @shafiarahman_:
✅ 1L Rx options
✅ AEs
✅ What next if disease was to progress on Daraxonrasib?
Full 🗣️:
⭐️ oncbrothers.com/cc-panc-2026
⭐️ “Oncology Brothers” podcast
#OncTwitter @OncoAlert @OncUpdates
Shaalan Beg MD MBA FASCO retweeted
Two great articles in #ASCOConnection on opportunities for volunteering and engagement at @ASCO.
connection.asco.org/do/guide…
connection.asco.org/do/asco-…
Shaalan Beg MD MBA FASCO retweeted
Trastuzumab plus nivolumab with GemCis as 1L
therapy for HER2-positive unresectable BTC: pls 1b/2 trial
@NatureMedicine
doi.org/10.1038/s41591-026-0…
👉ORR 55%, DCR 95%
👉mPFS 10.6 mo, mOS nr
🧐Promising, HERIZON BTC & DESTINY-BTC awaited
Shaalan Beg MD MBA FASCO retweeted
🚨⭐️Your Outlook email may not be working & your flight may be delayed ✈️ so you might have a few minutes to read our Perspective, just published hot off the press @Nature @Nature_NPJ
👉Open access, free for all to read - at least @X & internet are working :) #precisionmedicine #AI
👉"AI-based prediction of actionable genomic alterations from H&E-stained slides" 🔬
👉Tissue exhaustion & slow turnaround still keep patients from the right targeted therapy. Deep learning models can now predict actionable genomic alterations directly from routine H&E, and the prospective EAGLE (EGFR, NSCLC) and ANNAR (FGFR, urothelial) studies show this holds across diverse global cohorts.
👉Near-instant, non-destructive results let us triage patients for molecular testing or clinical trials at the time of diagnosis. Every lab in the world makes an H&E slide, and this puts molecular information within reach of all of them @OncoAlert @oncodaily
nature.com/articles/s41698-0…
Shaalan Beg MD MBA FASCO retweeted
Great perspective from @PauloBergerot in @ASCO Daily News on a critical challenge in #ExerciseOncology: moving beyond the optimal exercise dose to interventions that are feasible, accessible, and sustainable in patients’ everyday lives #ASCOQLTY26
dailynews.ascopubs.org/do/ca…
Shaalan Beg MD MBA FASCO retweeted
Our atlas of young-onset CRC is finally out in @NatureMedicine! We found a unique biology in younger patients that may explain the aggressive nature of this disease. This was a monumental effort with colleagues at @MassGenBrigham and @broadinstitute. @DFarberYoungCRC
Researchers co-led by @KimmieNgMD of @DanaFarber and @DFarberYoungCRC created the largest single-cell atlas of colorectal cancer ever, identifying age-associated differences that may help research into why #colorectalcancer can be more aggressive in younger adults. ➡️bit.ly/4kmBFEl
ASCO Members! You now get full access to ASCO Meetings content 30 days post-meeting. Explore the latest science faster! View content from the 2026 ASCO Annual Meeting: bit.ly/4hXg1DS
Coming soon: An AI-powered agent from ASCO & Google Cloud to simplify your research.
Shaalan Beg MD MBA FASCO retweeted
Dr. @QasimHussainiMD giving an amazing discussion of two studies on #ExerciseOncology presented at @ASCO Quality Care Symposium this morning.
asco.org/quality/program
#ASCOQLTY26 @crisbergerot @PauloBergerot
Shaalan Beg MD MBA FASCO retweeted
Fantastic oral abstract discussion by Dr. @CharlesJiangMD at @ASCO Quality Care Symposium today!
asco.org/quality/program?int…
#ASCOQLTY26 @utswcancer @UTSWMedCenter
Hey, @TimothyJBrownMD, can an F-150 do this?
Tesla unveiled a redesigned Roadster equipped with thrusters that enable it to fly short distances, nearly nine years after it first showed a next-generation version of its electric sports car, and said it would start production in 2028 reut.rs/4zt7Q9A
We have liftoff: Tesla's new Roadster can fly, sort of - Automotive
Shaalan Beg MD MBA FASCO retweeted
Great to see work from @ASCO Quality Care Symposium simultaneously published in @JCO_ASCO today:
“Effectiveness of a Multisite Oncology Financial Navigation Intervention: The Lessening the Impact of Financial Toxicity Clinical Trial.”
ascopubs.org/doi/pdf/10.1200…
#ASCOQLTY26
Geographical access to clinical trials remains the number one barrier to enrollment.
Look forward to hearing how technology-enabled services are being used by sites to improve access to cancer trials. #ascoqlty26
Growing excitement for the @ASCO Quality Care Symposium (#ASCOQLTY26) this week!
Nice overview of one of the studies on Decentralizing Clinical Trials being presented at the meeting:
dailynews.ascopubs.org/do/de…
@JamesFanWu @crisbergerot @ShaalanBeg
#CancerResearch #ClinicalTrials
Shaalan Beg MD MBA FASCO retweeted
Atezolizumab is now @FDA ✅ off #ATOMIC Ph III, adj mFOLFOX + Atezo vs. mFOLFOX in Stg III dMMR colon ca.
- 3yr DFS 86.4% vs 76.6% (HR 0.50)
- OS not mature
- ⬆️ Gr4 neutropenia with Atezo.
- How much is chemo benefitting? Role of NICHE2?
- @ASCO Plenary!
#gism #OncTwitter
How has teamwork transformed patient outcomes in your practice? Bring Dr. Elizabeth Mittendorf’s @ASCOPres theme—Intentional Teams. Exceptional Care.—to life on the #ASCO27 stage during the ASCO Voices session.
🎙️ Submit your audition by November 13: bit.ly/4ALUHts
Shaalan Beg MD MBA FASCO retweeted
Based off HER2CLIMB-05, Tucatinib is now @FDA ✅ as maintenance for HER2+ mBC, PhIII, THP —> HP +/-Tucatinib
- Improved PFS in all subsets
- mPFS: 24.9mos vs. 16.3mos (HR: 0.64)
- ⬆️ AEs with Tucatinib (LFTs & diarrhea)
#BreastCancer #bcsm #OncTwitter
Shaalan Beg MD MBA FASCO retweeted
We have 3 Anti-Her2 options today for Upper GI adenocarcinoma. Here is the table outlining dose, common toxicities, and clinical pearls in managing these AEs that we touched on during our #ToxCheck discussion with @ShrutiPatelMD & @Sam_Cytryn
#MedTwitter #MedX #OncTwitter
Tox-Check: Anti-Her2 drugs in Upper GI (Esophageal, GE Junction, and Gastric Adenocarcinoma) w/ @ShrutiPatelMD & @Sam_Cytryn
✅ Trastuzumab
✅ Zanidatamab
✅ TDXd
Full 🗣️:
⭐️ oncbrothers.com/toxcheck-her…
⭐️ “Oncology Brothers” podcast
#OncTwitter @OncoAlert @OncUpdates #gism
Shaalan Beg MD MBA FASCO retweeted
Getting ready to present the phase II GRECO-2 trial Tuesday at #ASTRO26. Can’t stop thinking of you, @TaniguchiMD. There is no way I can represent the purple hair like you did, but I’ll do my best to represent the SOD story.
Missing you, brother. RIP.
Shaalan Beg MD MBA FASCO retweeted
⭐️🚨Just published 👉🏼Pleased to share our standout new review 👉🏼published in @TheLancet @eClinicalMed 👉🏼led by 3 amazing rising stars ⭐️ @JiaJennyLiu @niamhjcoleman @JulianaRBeal
👉🏼“Tumour‑agnostic immunotherapy: aligning biological rationale, biomarker precision, and real‑world implementation.”
👉🏼 Tumour‑agnostic immunotherapy has reshaped precision oncology by showing that, in selected settings, treatment benefit can be driven by a shared biological state rather than anatomical origin. The clearest example: MSI‑H/dMMR cancers, where durable responses span diverse malignancies.
⭐️Such a delight to work with & mentor this dream team 👉🏼their clarity, rigor, and vision shine through every section 🎯🔥
@OncoAlert @oncodaily @OncBrothers
thelancet.com/journals/eclin…











































